Lundbeck A/S Banner Image

Lundbeck A/S has reached its limit for free report views

Work for Lundbeck A/S? Upgrade Your Profile and unlock all your responsibility reports.

Lundbeck A/S

  • Ticker
  • Industry --None-- More
  • Sector Healthcare More
Lundbeck A/S Logo Image
  • 5001-10,000 Employees
  • Based in Valby, Europe
H. Lundbeck A/S engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, North America, and internationally. The company's principal products include Abilify Maintena for schizophrenia; Brintellix/Trintellix to treat depression; Northera for the treatment of symptomatic neurogenic orthostatic hypotensionMore; Onfi for Lennox-Gastaut syndrome; Vyepti for migraine prevention; and Rexulti to treat depression/schizophrenia. It also provides Azilect for treating Parkinson's disease; Cipralex/Lexapro for depression; Ebixa to treat Alzheimer's disease; Sabril for treating epilepsy; and Xenazine for chorea associated with Huntington's disease, as well as other products. The company sells its products primarily to distributors of pharmaceuticals, pharmacies, and hospitals. It has a partnership agreement with Verantos to focus on a study to enable real-world evidence in support of migraine therapy. The company was founded in 1915 and is headquartered in Valby, Denmark.
Lundbeck A/S

Most Recent Responsibility Report

Lundbeck A/S
MOST RECENT 2021 Sustainability Report

Report Locked. Lundbeck A/S has reached its limit for free report views.

Archived Responsibility Reports

Our service enables potential investors to review the most recent and archived Lundbeck A/S Sustainability Report, Lundbeck A/S Corporate Social Responsibility Report, Lundbeck A/S CSR Report, Lundbeck A/S Corporate Responsibility, Lundbeck A/S CR Report, Lundbeck A/S Citizenship Report, Lundbeck A/S ESG Report, and Lundbeck A/S Environmental Report online.